Sands Capital Management, LLC Mirati Therapeutics, Inc. Transaction History

Sands Capital Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 12, 2021	SELL	$158.92 - $221.61 $62.6 Million - $87.3 Million	-393,886 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$162.05 - $240.27 $152 Million - $225 Million	-936,816 Reduced 70.4%	393,886 $86.5 Million
Q3 2020 Nov 16, 2020	SELL	$113.26 - $167.27 $94.9 Million - $140 Million	-837,870 Reduced 38.64%	1,330,702 $221 Million
Q2 2020 Aug 11, 2020	SELL	$72.01 - $120.39 $5.72 Million - $9.56 Million	-79,437 Reduced 3.53%	2,168,572 $248 Million
Q1 2020 May 14, 2020	BUY	$69.78 - $116.21 $31.1 Million - $51.9 Million	446,269 Added 24.77%	2,248,009 $173 Million
Q4 2019 Feb 13, 2020	BUY	$70.76 - $128.86 $33.3 Million - $60.7 Million	470,757 Added 35.37%	1,801,740 $232 Million
Q3 2019 Nov 14, 2019	SELL	$77.91 - $109.6 $3.79 Million - $5.33 Million	-48,631 Reduced 3.52%	1,330,983 $104 Million
Q2 2019 Aug 14, 2019	BUY	$59.49 - $104.71 $82.1 Million - $144 Million	1,379,614 New	1,379,614 $142 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Sands Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sands Capital Management, LLC with notifications on news.